Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      • Home
      • Medical Dialogues...

      Articles By : Medical Dialogues Bureau

      Undeterred by Sanofi stumble, Takeda takes similar path with dengue shot

      Undeterred by Sanofi stumble, Takeda takes similar path with dengue shot

      Medical Dialogues Bureau31 Jan 2019 9:00 AM IST
      The strategy mirrors one used by Sanofi SA, which licensed the world's first dengue vaccine, Dengvaxia, in endemic markets in 2015 before attempting...
      Strides to exit investment in Arrow Pharma for over Rs 2000 crore

      Strides to exit investment in Arrow Pharma for over Rs 2000 crore

      Medical Dialogues Bureau30 Jan 2019 9:30 AM IST
      "Strides will receive AUD 300 million as upfront payment at the closure of the transaction, while the balance AUD 94 million to be deferred through a...
      U.S. senator asks J&J for documents on talc, baby powder safety

      U.S. senator asks J&J for documents on talc, baby powder safety

      Medical Dialogues Bureau30 Jan 2019 9:15 AM IST
      The letter addressed to J&J Chief Executive Alex Gorsky asks for documents and information related to testing of its talc products for the...
      Dr. Reddys gets USFDA approval for TOSYMRA for treatment of migraine

      Dr. Reddy's gets USFDA approval for TOSYMRA for treatment of migraine

      Medical Dialogues Bureau29 Jan 2019 9:45 AM IST
      TOSYMRA is indicated for the acute treatment of migraine with or without aura in adults. TOSYMRA is the latest product to join the Promius Pharma...
      Zydus Wellness to sell shares worth Rs 2575 crore to Cadilla and three others

      Zydus Wellness to sell shares worth Rs 2575 crore to Cadilla and three others

      Medical Dialogues Bureau29 Jan 2019 9:20 AM IST
      In a tweet Friday, the Competition Commission of India (CCI) said it "approves the acquisition of shares in Zydus Wellness Limited by True North...
      Exclusive: CVS to cover migraine drugs from Teva, Lilly; excludes Amgen

      Exclusive: CVS to cover migraine drugs from Teva, Lilly; excludes Amgen

      Medical Dialogues Bureau29 Jan 2019 9:00 AM IST
      The move by CVS is a positive development for Teva, whose drug was initially excluded from the list of covered drugs by Express Scripts, another large...
      Manufacturer to pay penalty for entire batch if single drug found substandard: Govt New Proposal

      Manufacturer to pay penalty for entire batch if single drug found substandard: Govt New Proposal

      Medical Dialogues Bureau28 Jan 2019 3:04 PM IST
      New Delhi : Even if a single drug in a batch is found substandard the manufacturer may have to pay a penalty equal to the MRP of the entire batch...
      Lupin gets 6 observations from USFDA for its Pithampur Unit-2

      Lupin gets 6 observations from USFDA for its Pithampur Unit-2

      Medical Dialogues Bureau28 Jan 2019 1:20 PM IST
      NEW DELHI: Drug firm Lupin Saturday said the US health regulator has issued six observations after the inspection of a unit of its Pithampur facility...
      Price Ceiling, Compulsory licensing of patented medicines Necessary: Govt panel

      Price Ceiling, Compulsory licensing of patented medicines Necessary: Govt panel

      Medical Dialogues Bureau28 Jan 2019 12:50 PM IST
      Worried about "high prices" and "unaffordability" of patented medicines in India, the Department of Pharmaceuticals (DOP) formed this...
      Aurobindo recalls nearly 5 lakh bottles of blood pressure drug in US

      Aurobindo recalls nearly 5 lakh bottles of blood pressure drug in US

      Medical Dialogues Bureau28 Jan 2019 12:41 PM IST
      New Delhi: Drug firm Aurobindo is recalling close to 5 lakh bottles of blood pressure lowering drugs in the US after the American health regulator...
      Glenmark Pharma gets tentative ANDA approval for Topiramate Extended-Release Capsules

      Glenmark Pharma gets tentative ANDA approval for Topiramate Extended-Release Capsules

      Medical Dialogues Bureau28 Jan 2019 9:00 AM IST
      Mumbai: Glenmark Pharma said that it US subsidiary Glenmark Pharmaceuticals Inc., USA has been granted tentative approval by the United States Food...
      Bristol Myers pulls FDA application for Opdivo combination in lung cancer

      Bristol Myers pulls FDA application for Opdivo combination in lung cancer

      Medical Dialogues Bureau27 Jan 2019 9:30 AM IST
      Opdivo, Bristol’s most important growth driver, has lost much of its lustre as Merck & Co’s rival drug Keytruda seized dominance in advanced lung...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok